AI in Medicine News ・ 🏥 Hospital operations and care delivery
Pulse 2.0 · 11/14 13:56 UTC

Orakl Oncology, an AI-driven biotechnology company developing technologies to improve the prediction of cancer drug responses, has raised $34 million in Series A funding co-led by Norrsken VC and Singular. The financing will support its expansion, international hospital partnerships and development of its AI platform. The platform combines patient-derived tumor samples, clinical information and experimental biological data to advance oncology drug research.